Vascular endothelial growth factor receptor 2 (VEGFR2) is a primary responder to vascular endothelial growth factor signal and thereby regulates endothelial migration and proliferation. This receptor is expressed in endothelial cells and in some vascular tumors, but many reports also detail its expression in carcinomas and lymphomas. VEGFR2 is a potential cell-type marker, and data on VEGFR2 expression may also have therapeutic significance in view of recent availability of VEGFR2 inhibitors. In this study, we immunohistochemically examined 262 vascular endothelial and 1640 nonvascular tumors and selected non-neoplastic tissues with a VEGFR2-specific rabbit monoclonal antibody 55B11. In early human embryo, VEFGR2 was expressed in endothelia of developing capillaries and in the thoracic duct, great vessels, hepatic sinusoids, epidermis, and mesothelia. In late first trimester fetus peripheral soft tissues, VEGFR2 was restricted to capillary endothelia, chondrocytes, and superficial portion of the epidermis. In normal adult tissues, it was restricted to endothelia and mesothelia. VEGFR2 was consistently expressed in angiosarcomas, Kaposi sarcomas, and retiform hemangioendotheliomas. It was detected in only half of epithelioid hemangioendotheliomas (15/27), usually focally. VEGFR2 was strongly expressed in most capillary hemangiomas and weakly or focally in cavernous, venous, and spindle cell hemangiomas and in lymphangiomas. Malignant epithelial mesothelioma was found to be a unique epithelial neoplasm with a strong and nearly consistent VEGFR2 expression, including membrane staining (35/38). Approximately 10% of squamous cell carcinomas and 23% of pulmonary adenocarcinomas contained focal positivity. The only nonendothelial mesenchymal tumors found to be VEGFR2 positive were biphasic synovial sarcoma (focal epithelial expression) and chordoma. All melanomas and lymphomas were negative. VEGFR2 is a promising marker for malignant vascular tumors and malignant epithelioid mesothelioma. Expression in biphasic synovial sarcoma epithelium, chordoma, and some carcinomas has to be considered in differential diagnosis. Information on VEGFR2 tissue expression may be useful in development of targeted oncologic therapy through VEGFR2-specific tyrosine kinase inhibitors.
V ascular endothelial growth factor receptor 2 (VEGFR2) is a type V receptor tyrosine kinase mainly known to be expressed in vascular endothelial cells and encoded by the KDR gene. This receptor responds to the signal of vascular endothelial growth factor (VEGF) binding, which initiates a phosphorylation cascade that ultimately involves nuclear regulatory targets resulting in enhancement of endothelial proliferation and migration. 32 VEGFR2 protein is also known as KDR (kinase insert domain receptor), Flk-1 (fetal liver kinase 1), or CD309 in the cluster of differentiation terminology of hematopoietic antigens. VEGFR2 is expressed in many but not all vascular endothelial cells from early fetal development, and it is more highly expressed in neovascular tumor endothelia than in normal endothelia. 5, 33 VEGFR2 expression has been reported in hemangiomas and angiosarcomas. Activated VEGFR2 signaling, 15 sometimes by KDR gene mutations found in juvenile capillary hemangiomas and angiosarcomas, is believed to be pathogenetically important. 2, 35 However, no systematic information exists on VEGFR2 expression in vascular tumors.
Numerous studies have reported VEGFR2 expression in carcinoma cells, especially in mammary, 12, 28 colorectal, 1,10,31 lung non-small-cell, 9, 30 and urothelial 36 carcinomas. Tumor cell expression has also been reported in malignant melanoma 18, 27 and diffuse large B-cell lymphoma. 13 However, a recent report on common carcinomas failed to detect VEGFR2 in tumor cells and found it limited to tumor endothelia only. 33 Recent arrival of tyrosine kinase inhibitors with specificity toward VEGFR2, such as sunitinib, sorafenib, and cabozanitib, and VEGFR2 blocking by a VEGFneutralizing antibody bevacizumab (analogous to herceptin in breast cancer) have generated expectations that these inhibitors could be effective against VEGFR2-positive tumors as targeted oncologic therapy, whereas the antiangiogenic effect in any tumor (whether or not expressing VEGFR2) could also have additional or independent therapeutic effects. 2, 6, 17, 37 In this study, we systematically examined vascular endothelial, nonendothelial epithelial, mesenchymal, neuroectodermal, and hematolymphoid tumors for VEGFR2 to examine its endothelial specificity and the potential of VEGFR2 as a tumor-type marker and also to discover potential targets for VEGFR2 inhibitor-based targeted therapy. We used a monoclonal antibody 55B11 shown specific to this receptor. 33 Our results confirm that VEGFR2 is a strong marker for angiosarcoma and Kaposi sarcoma and has very limited expression in nonendothelial mesenchymal and neuroectodermal tumors. Among epithelial tumors, its consistent and unique expression in malignant mesothelioma is of interest for both tissue diagnosis and targeted therapy with VEGFR2 inhibitors.
MATERIALS AND METHODS

Tissues
Selected normal developing and adult tissues and 262 vascular endothelial tumors were evaluated. Also studied for comparison were 793 nonendothelial mesenchymal tumors and 847 epithelial neoplasms (almost all malignant). Most of these tissues were arranged in tightly packed multitissue blocks containing 25 to 50 cases. Thus, the tissue volume was on average far greater than that in tumor microarrays based on 0.6 to 1 mm punch biopsies; hence, such multitissue blocks are sometimes referred to as "macroarrays." All tissues were obtained from surgical specimens and used in an anonymized manner. All angiosarcomas were verified as CD31 positive and Kaposi sarcomas as HHV8 positive. Other tumors were extensively verified by multiple differentiation markers. Especially, all "outliers," unexpectedly positive or negative cases, were further investigated and verified to confirm the diagnostic category.
Immunohistochemistry
A rabbit monoclonal VEGFR2-specific antibody 55B11 from Cell Signaling Technology (Danvers, MA) was used at a dilution of 1:500. Immunostaining was performed using a Leica Bond-Max automated immunostainer. Heatinduced epitope retrieval was performed for 30 minutes using a Bond-Max high-pH epitope retrieval buffer. Primary antibody was applied for 30 minutes, followed by Bond-Max polymer for 15 minutes. Diaminobenzidine was used as the chromogen, followed by a hematoxylin counterstain.
The percentage of positive tumor cells was estimated. The presence of internal control (positive capillary endothelia) was required for valid immunostaining for tumors, but this was not required in normal tissues; however, external control was used to verify technical adequacy for each slide. Parallel data on vascular tumors were available on other endothelial markers from previous studies: claudin-5, ERG, Prox1, podoplanin, and CD31. [21] [22] [23] 
RESULTS
The results of VEGFR2 immunoreactivity in 262 vascular endothelial cell tumors, 793 nonendothelial mesenchymal and lymphohematopoietic tumors, and 847 epithelial neoplasms (mostly malignant) have been summarized in Tables 1 to 3. 
Developing Human Tissues
In an early first trimester embryo (estimated age, 7 wk), VEGFR2 immunoreactivity was present in the epidermis, vascular endothelial cells ( Figs. 1A, B ), and mesothelial cells. Small capillaries with positive endothelia were detected in primitive placenta and in the truncal, intestinal, and pulmonary mesenchyme. Of the large truncal vessels, prominent positivity was detected in the thoracic duct and in structures consistent with the orifices of the great vessels of the heart. Within the heart, endothelial staining was more prominent in the atria and peripheral portions of the ventricles and in the orifices of the great vessels. In the liver, sinusoids were positive (Fig. 1C ). Portal tracts were not identifiable. Mesothelial cells were variably positive. All parenchymal epithelial, nonendothelial mesenchymal, and primitive neural elements were negative.
In a late first trimester fetus limb, VEGF2 positivity was detected in capillary endothelia, in the upper portion of the epidermis, and in the cartilage.
Non-neoplastic Adult Tissues
VEGFR2 immunoreactivity was essentially restricted to endothelia and mesothelia ( Fig. 1D ), and no parenchymal epithelia or neural, lymphoid, or muscular tissues were positive. Small positive capillaries were noted in the soft tissue, nasal and gastrointestinal tract, urinary bladder mucosae, and in lymphoid and subepithelial tissues of the tonsil, pancreas, and myocardium. In the kidney, glomerular endothelia were strongly positive, and interstitial capillaries were weakly positive. In normal adult liver, positivity was restricted to portal vessels, and sinusoids were negative. The spleen contained positive capillaries in the red pulp, whereas sinusoidal and muscular venous and arterial endothelia were negative. In addition, muscular walls of some venules were weakly positive. No positive capillaries were detected in the brain and prostate, and very few were detected in the muscular layers of the gastrointestinal tract. Peritoneal mesothelia showed regionally variable positivity. Submesothelial (keratin-positive) cells in regenerative processes adjacent to the peritoneal surface were also variably positive. 
Benign Angiomas
The results are summarized in Table 1 and illustrated in Figure 2 . Hemangiomas varied in their VEGFR2 immunoreactivity. Typically strongly positive were juvenile capillary hemangiomas, lobular capillary hemangiomas ( Fig. 2A) , and other types of capillary hemangiomas. Papillary endothelial hyperplasia components in various hemangiomas were also strongly positive. All 4 epithelioid hemangiomas showed VEGFR2 immunoreactivity in the majority of epithelioid endothelial cells.
Cavernous and venous hemangiomas typically showed weak, delicate staining ( Fig. 2B ) observed only in a varying number of lining cells (median, 25%). Hepatic cavernous hemangiomas often showed stronger staining than the peripheral examples. Spindle cell hemangioma endothelia were heterogenous, and in most cases only a minority of lining cells were positive (median, 20%; Fig. 2C ), whereas the spindle cells were negative. Lymphangiomas also typically showed limited, delicate VEGFR2 immunoreactivity usually in a minority of vascular endothelia (median, 30% of endothelia; Fig. 2D ). In 1 lymphangioendothelioma, 80% of lining cells were VEGFR2 positive.
Hemangioendotheliomas
Kaposiform hemangioendothelioma (Table 1) showed a VEGFR2-positive endothelial component, whereas the pericytes were negative (Fig. 3A) . Dabska hemangioendothelioma components in a lymphangioma were strongly positive. All but 1 of 12 retiform hemangioendotheliomas showed strong positivity in the majority of tumor cells ( Fig. 3B ). However, only half of epithelioid hemangioendotheliomas were positive. In those tumors, the positivity was focal (median, 20% of tumor cells), often membrane associated (Fig. 3C) . One epithelioid sarcoma-like hemangioendothelioma was negative. 
Kaposi Sarcoma and Angiosarcomas
All Kaposi sarcomas (Table 1) were positive with moderate-to-strong intensity of apparently cytoplasmic staining (Fig. 3D ). Most angiosarcomas irrespective of site of origin or subtype were strongly positive for VEGFR2 (85/89, 96%) with variable membranous and cytoplasmic staining (Figs. 4A-D). In addition, some angiosarcomas also showed perinuclear Golgi zone-like positivity. Only 3 cases showed positivity in 10% or less of tumor cells, and 8 of 9 epithelioid angiosarcomas were positive. The 4 VEGFR2-negative angiosarcomas were poorly differentiated examples: 1 each from the buttock, stomach, pericardium, and brain. However, solid nonvasoformative angiosarcomas were often positive. Such a tumor involving the small intestine was highlighted as a sole VEGFR2-positive case in a block containing largecell lymphomas. This tumor was also positive for CD31, ERG, claudin-5, and Prox1 ( Fig. 5 ) and was negative for CD20 and Pax5.
Malignant Epithelial Neoplasms
The results are summarized in Table 2 . The most striking and consistent tumor cell-specific VEGFR2 positivity was detected in malignant epithelial mesothelioma, of which 35/38 cases (92%) were positive, typically with extensive, predominantly membrane staining with some cytoplasmic positivity (Fig. 6A ). Tubulopapillary examples showed stronger staining, whereas solid epithelial proliferations were variably, often only focally positive. Three purely solid epithelial mesotheliomas and all 6 sarcomatoid spindle cell mesotheliomas were negative.
Focal diffuse cytoplasmic positivity without distinct membrane staining was detected in 12/53 (23%) pulmonary adenocarcinomas (Fig. 6B ). Approximately 10% of cutaneous, laryngeal, esophageal, and pulmonary squamous cell carcinomas contained focal cytoplasmic positivity ( Fig. 6C ). All other carcinomas and testicular seminomas were VEGFR2 negative ( Table 2 ). Nearly half of testicular embryonal carcinomas (6/15) contained clusters of positive epithelial cells with both membranous and cytoplasmic staining (Fig. 6D) , whereas all seminomas were negative.
In addition to the above-described tumor cell immunoreactivity, VEGFR2 was detected in tumor neovascular endothelia, especially prominently in renal cell and pulmonary small-cell carcinomas and also in malignant mesotheliomas.
Nonendothelial Mesenchymal and Hematopoietic Tumors
VEGFR2 immunoreactivity was limited in mesenchymal nonendothelial tumors. Biphasic synovial sarcoma (7/8) contained glandular epithelial cells with cytoplasmic VEGFR2 positivity (Table 3 ; Fig. 7) . Half of the chordomas (5/10) contained cytoplasmic positivity. All other mesenchymal and neuroectodermal tumors studied, including melanomas, granulosa cell and Leydig cell tumors, and small and large B-cell lymphomas and T-cell lymphomas, were negative.
DISCUSSION
In this study, we immunohistochemically evaluated expression of VEGFR2, a vascular endothelial growth factor receptor that regulates endothelial proliferation and migration. We used a monoclonal rabbit antibody 55B11 previously found specific to this receptor tyrosine kinase. 33 The results showed expression in normal endothelia and mesothelia and widespread expression of VEGFR2 in benign and malignant vascular tumors. In addition, VEGFR2 was detected in a small fraction of epithelial neoplasms, most notably in malignant mesothelioma and testicular embryonal carcinoma and to a lesser degree in pulmonary adenocarcinoma and squamous cell carcinomas. Although VEGFR2 is a membrane protein, and thus membrane immunoreactivity is expected, some tumors also showed diffuse cytoplasmic or Golgi zone-like paranuclear positivity. This distribution may reflect aberrant processing of the VEGFR2 protein in tumors.
VEGFR2 is strongly expressed in most angiosarcomas regardless of subtype, site, and differentiation but was absent in nonendothelial malignant mesenchymal tumors, with very rare exceptions (biphasic synovial sarcoma, chordoma). VEGFR2 was also detected in all Kaposi sarcomas, indicating that this receptor can be a useful supplemental marker for malignant vascular endothelial tumors. Ability of VEGFR2 to identify poorly differentiated angiosarcomas randomly present in multitumor blocks containing different tumor entities further illustrates its diagnostic usefulness. Similar to other endothelial markers, VEGFR2 does not discriminate between benign and malignant endothelial neoplasms; hence, this distinction must be made on histologic grounds. Previous studies have demonstrated VEGFR2specific mRNA in angiosarcoma and Kaposi sarcoma, 3 and a small number of angiosarcomas were shown to be immunohistochemically VEGFR2 positive. 2 Because of the strong VEGFR2 expression in vascular tumors and presence of VEGFR2-mutations in some angiosarcomas (10% in 1 study), 2 tyrosine kinase inhibitors with specificity toward VEGFR2 are being investigated as targeted oncologic therapy for malignant vascular tumors. 2, 26 Our results showing strong VEGFR2 expression in angiosarcomas regardless of differentiation level support the basis of VEGFR2 inhibitors as targeted therapy against malignant endothelial tumors.
Compared with other endothelial markers, VEGFR2 is nearly equally specific and sensitive for angiosarcoma as CD31 and ERG, each marker having different additional specificities: mesothelia/mesothelioma for VEGFR2, histiocytes and plasma cells for CD31, 19, 20 and prostate cancer and cartilage for ERG. 21 VEGFR2 is more specific than claudin-5, which also labels a large number of various carcinomas, 22 and more sensitive and specific than podoplanin (D2-40) and Prox1, each of which labels only a subset of angiosarcoma (especially the cutaneous ones) and additionally many types of carcinomas and other tumors. 16, 23 VEGFR2 expression in hemangiomas is more variable, with some variants, such as juvenile capillary and lobular capillary hemangiomas, showing strong positivity, whereas other capillary and many cavernous hemangiomas showed more subtle positivity, probably reflecting weaker expression. As noted in previous studies, VEGFR2 showed stronger expression in neovascular endothelia or carcinomas. 33 In hemangioendotheliomas, VEGFR2 expression is variable. Whereas the more differentiated and vasoformative types, such as kaposiform and retiform hemangioendotheliomas, are strongly positive, epithelioid hemangioendotheliomas with primitive vasoformation are only focally, if at all, positive, indicating that other vascular endothelial markers such as CD31, ERG, and claudin-5 are more suitable for its detection. 7, 21, 22 VEGFR2 expression in nonendothelial mesenchymal tissues and tumors is rare. However, this receptor is expressed at least in fetal cartilage, as also reported by others, 4 and therefore might also be expected in cartilaginous tumors. On the basis of our observation, chordoma also seems to commonly contain VEGFR2-positive tumor cells, perhaps as a reflection of its distant relationship with cartilage.
Malignant epithelial mesothelioma is a notable exception as a strongly VEGFR2-positive epithelial neoplasm. VEGFR2 expression of mesothelioma parallels its expression in normal adult (and fetal) mesothelial cells. VEGFR2 is therefore a new supplemental positive marker for malignant mesothelioma, along with calretinin, keratins 5, and WT1. However, additional mesothelial/epithelial and vascular markers may be needed to separate mesothelioma from angiosarcoma, another tumor with strong VEGFR2 expression. Because sarcomatoid mesotheliomas lack VEGFR2 expression, this marker is not suitable for their detection. Similarly, some solid epithelial mesotheliomas also show limited or, in some cases, no expression.
On the basis of strong VEGFR2 expression in mesothelioma cells, this tumor would be a particularly strong candidate for targeted therapy with VEGFR2 tyrosine kinase inhibitors. Indeed, in vitro studies have demonstrated that tyrosine kinase inhibitors sunitinib and vandetanib, which mainly inhibit VEGFR2, inhibited growth of 3 mesothelioma cell lines. 25 Also, all 17 mesothelioma tissue sections were immunohistochemically positive with the 5B11 antibody; this result was confirmed in the present study. Similarly, VEGFR2 inhibitors might also be of interest in VEGFR2-positive chordomas, a 50% subset of these tumors, on the basis of our findings.
Embryonal carcinoma of the testis was another epithelial tumor with distinct membranous VEGFR2 positivity. Such positive cells were seen in clusters as a minority of tumor cells. It is difficult to ascertain their nature, but early vascular or mesothelial progenitor type of differentiation is possible. It is of interest to note that angiosarcoma is the second most common somatic evolution into a sarcoma in germ cell tumors, after rhabdomyosarcoma. 8 VEGFR2 was otherwise rarely expressed in common carcinomas, in general agreement with a recent study with the same 55B11 antibody. 32 In our study, no carcinomas of breast, colon, endometrium, ovary, pancreas, prostate, or stomach were positive. However, 23% of pulmonary adenocarcinomas contained positive cells. Their focal cytoplasmic positivity, however, was in contrast to the membrane staining observed in most mesotheliomas; hence, the pattern of staining (membrane vs. cytoplasmic) can be useful in separation of mesothelioma from pulmonary adenocarcinoma.
Our results and those of Smith et al, 33 who found either rare or no VEGFR2 expression in common carcinomas, are in contrast with those of numerous older studies, in which 40% or more of carcinomas, such as pulmonary non-small-cell carcinomas 9, 30 and mammary, 12,28 colorectal, 1,10,31 gastric, 34 and transitional cell carcinomas of the bladder, 36 were found to have VEGFR2 expression in tumor cells; this difference is most likely attributable to use of specific (less staining) versus nonspecific antibodies (more staining). We also found no VEGFR2 expression in hepatocellular carcinoma, in contrast with a previous study reporting this receptor in 61% of hepatomas with the authors' own antibody. 14 Because many of these studies report tumor cell VEGFR2 expression as an adverse prognostic factor, these findings may have to be reinterpreted.
VEGFR2 expression was also detected in approximately 10% of squamous cell carcinomas. This finding might correspond with the fetal squamous epithelial phenotype with VEGFR2 positivity. Thus, VERGR2 positivity in some squamous cell carcinomas might represent oncofetal antigen expression-reversion of tumor expression pattern into that of fetal tissue. A previous study using another VEGFR antibody showed a higher frequency of VEGFR2 in head and neck squamous carcinomas, with nearly all cases (17/18) being focally positive. 24 However, another report stated VEGFR2 negativity of head and neck squamous cell carcinoma cells, observing positive stromal cells instead. 29 We were also not able to replicate previous findings showing common (>50%) cytoplasmic VEGFR2 expression in diffuse large B-cell lymphomas, 13 malignant melanomas, 18, 27 and ovarian granulosa cell tumors. 11 Those studies with VEFGR2-positive findings were also based on VEGFR2 antibodies determined unspecific by a recent investigation, 33 or the antibody source was not stated. The less frequent true VEGFR2 expression carcinomas and absence of this receptor in lymphoma and melanoma cells may lead to modification of oncologic strategies related to the use of VEGFR2-specific inhibitors, unless these inhibitors are used merely against tumor neovascularization.
In summary, we evaluated a large number of vascular and nonvascular endothelial tumors. Consistent expression of VEGFR2 in angiosarcoma and Kaposi sarcoma, together with limited expression in other mesenchymal and epithelial tumors, makes this marker potentially useful in the diagnosis of malignant vascular tumors. Strong VEFGR2 expression in malignant epithelioid mesothelioma and relatively rare expression in other epithelial tumors make this marker a worthy supplemental marker for epithelial malignant mesothelioma. Furthermore, the results strengthen the basis for application of tyrosine kinase inhibitors with specificity to VEGFR2 in targeted oncologic treatment of malignant vascular tumors and epithelial mesothelioma.
